Surgical Success: How to Identify the Right Liver Cancer Patients
"A novel approach using localized therapy could revolutionize liver cancer treatment by carefully selecting patients who will benefit most from surgery."
Hepatocellular carcinoma (HCC), a type of liver cancer, often presents with a serious complication: portal vein tumor thrombosis (PVTT). This means the cancer has invaded the main vein that carries blood to the liver, making treatment challenging. Historically, HCC with PVTT has a poor prognosis, with patients surviving less than a year.
While surgery offers the best chance for long-term survival, it's not suitable for everyone. Identifying which patients will truly benefit from surgery is crucial. Researchers have been exploring ways to improve patient selection and outcomes, leading to innovative treatment strategies.
One such strategy involves using localized concurrent chemoradiotherapy (CCRT) followed by hepatic arterial infusion chemotherapy (HAIC). This approach aims to shrink the tumor and control its spread before considering surgery. A recent study investigated whether this combination can help identify optimal surgical candidates among HCC patients with PVTT.
The Global Burden of Liver Cancer
SEER reports that the rate of new liver and intrahepatic bile duct cancer cases is 9.5 per 100,000 men and women annually, while the death rate is 6.6 per 100,000. A 2023 global analysis reported 854,000 incident liver cancer cases in 2015, alongside 810,000 deaths and 20,578,000 disability-adjusted life years. UK data also show substantial national variation, including 5,457 new cases in England in 2020. In England in 2022, 26% of patients received systemic anti-cancer therapy, 9% received radiotherapy, and 26% underwent surgery as part of their primary treatment.
Balancing Tumor Removal and Liver Function
Surgical resection for hepatocellular carcinoma and intrahepatic cholangiocarcinoma is based on achieving margin-negative removal while preserving adequate function in the remaining liver. A 2020 review states that laparoscopic liver resection is strongly indicated for small tumors under 2 cm, but is not recommended when more than four tumors occupy different portions of the liver. The EASL and AASLD guidelines generally limit resection to single tumors of any size, whereas APASL guidance is described as more permissive. These criteria illustrate why tumor number, distribution, size, and residual liver function constrain the surgical approach.
From Early Excision to Modern Surgery
The recorded history of liver surgery extends from the Ancient Greek myth of Prometheus to major clinical achievements over the past century. In 1891, Lucke reported the first successful excision of a malignant liver tumor. In 1899, Keen performed the first anatomic left lateral liver resection. Modern treatment now includes both tumor resection and liver transplantation, and some patients may receive chemotherapy before surgery to shrink a tumor depending on the diagnosis, stage, and other factors.
Localized Therapy: A Game-Changer for Surgical Selection?
The study evaluated the impact of localized CCRT and HAIC on subsequent surgical resection. The goal was to determine if this combined treatment could effectively select patients who would benefit most from surgery. The researchers compared outcomes of patients who underwent immediate resection versus those who received CCRT/HAIC followed by resection if their tumors responded.
- Improved Resection Rates: Downstaging with CCRT led to a 26.5% resection rate.
- Second-Order PVTT Advantage: Patients with second-order PVTT (tumor thrombus further away from the main portal vein) had a higher resection rate (50%) compared to first-order PVTT (21%).
- Favorable Tumor Biology: Patients with second-order PVTT demonstrated better responses to treatment, suggesting a less aggressive tumor type.
Expanding the Role of Liver Resection
Recent reviews examine the main indications for liver resection in hepatocellular carcinoma and compare surgery with percutaneous ablation and other liver-directed treatments. Another review reports that increased use of parenchymal-sparing surgery for bilateral colorectal liver metastases is associated with improved mortality. A study reported by City of Hope also describes liver cancer surgery becoming feasible as a safe outpatient procedure in selected patients. Together, these sources point to research focused on preserving liver tissue, refining patient selection, and reducing the burden of recovery.
The Risks of Removing Liver Tissue
Liver dysfunction and liver failure remain important risks after hepatectomy, particularly when the amount removed is substantial or the patient's liver is already impaired. Cancer Research UK lists bile leakage, liver failure, abdominal fluid buildup, infection, and blood clots among possible problems after resection. Another surgical source notes that liver failure may occur when the remaining liver tissue is insufficient to maintain normal function. These risks make the adequacy and health of the future liver remnant central to deciding whether surgery is appropriate.
Resection Versus Ablation
A 2025 study recommends liver resection as a first-line treatment for hepatocellular carcinoma, while identifying radiofrequency ablation as a preferable option for patients who are not suitable for surgery. In a cohort of 720 patients, liver resection was associated with significantly higher 1-, 3-, and 5-year survival rates than percutaneous radiofrequency ablation. These findings support surgery for appropriate candidates but do not make it suitable for everyone. Treatment selection therefore depends both on comparative outcomes and on whether a patient can safely undergo an operation.
The Future of Liver Cancer Treatment: Personalized Approaches
The study highlights the importance of personalized treatment strategies in liver cancer. As Blake Cady wisely stated, "biology is king, selection is queen." The presence of PVTT indicates aggressive tumor behavior, making careful patient selection crucial for successful surgical outcomes.
Matching Treatment to Tumor and Patient
A systematic review describes liver cancer as the sixth most prevalent malignancy globally and the fourth most common cause of cancer-related death. It also distinguishes primary hepatic tumors, including hepatocellular carcinoma, hepatoblastoma, and biliary-tree tumors such as intrahepatic cholangiocarcinoma, from metastatic disease that reaches the liver from organs such as the colon. For recurrent liver cancer, a 2025 review describes liver resection as the most effective and curative treatment while examining laparoscopic repeat resection as an option. Comparisons of resection and percutaneous thermal ablation report similar efficacy and survival for primary and secondary tumors no larger than 3 cm, although resection remains the most widely used strategy and ablation is generally reserved for patients who are not surgical candidates.
Making More Patients Operable
Regenerative liver surgery aims to increase the future liver remnant to an appropriate size before resection. Newer laparoscopic and robotic-assisted techniques are reported to typically cause fewer side effects and support faster recovery. Mayo Clinic describes a broader strategy for expanding eligibility through risk assessment, surgical planning, and perioperative optimization. The direction of progress is therefore not only toward new operations, but also toward preparing more patients to undergo existing ones safely.
Biology and Anatomy Complicate Surgery
A discussion of challenges in liver cancer reports that surgical intervention can depress cell-mediated immunity, reduce concentrations of anti-angiogenic factors, and increase pro-angiogenic factors. Separate clinical commentary emphasizes that the tumor's location can create additional surgical challenges. These concerns show that the operation is shaped not only by whether a tumor can be removed, but also by its biological effects and anatomical position. Patient selection must therefore account for both systemic consequences and technical complexity.
Individual Cases Defy Simple Categories
A Cleveland Clinic case study describes a 77-year-old patient who had been denied surgery elsewhere before undergoing complex liver resection for hepatocellular carcinoma with outstanding results. Another case study concerns a 33-year-old patient with metastatic colorectal cancer whose liver treatment improved the chance of living longer, although ovarian drop metastases later developed. UVA Health presents a Richmond patient with a very rare cancer who required a liver transplant to prevent further disease progression. These cases illustrate why surgical candidacy can depend on individualized assessment rather than age, prior opinions, or a single standard pathway.
While surgical resection remains the primary hope for a cure, reliable patient selection criteria have been lacking. This research demonstrates that downstaging achieved with localized CCRT can serve as an effective tool for identifying optimal surgical candidates with favorable tumor biology.
However, the retrospective nature and limited sample size of the study call for further prospective research. Future investigations should focus on identifying factors associated with radiologic response after CCRT to refine the downstaging strategy and maximize patient benefits. Additionally, exploring factors that promote liver regeneration after localized CCRT is essential to increase resectability and improve outcomes.